Drug Profile

ORKA 002

Alternative Names: ORKA 021; ORKA-002; PR-029

Latest Information Update: 28 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paragon Therapeutics
Developer Oruka Therapeutics; Paragon Therapeutics
Class Antibodies; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Interleukin 17 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Psoriasis; Psoriatic arthritis

Most Recent Events

12 Jan 2026 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in healthy volunteers released by Oruka Therapeutics
12 Jan 2026 Oruka Therapeutics plans a phase II trial in Hidradenitis suppurativa in the second half of 2026
12 Nov 2025 Oruka Therapeutics plans a phase II trial in Hidradenitis suppurativa (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com